馃敼 Adj. EPS: $1.39 (Est. $1.36) 馃槓; UP +7% YoY
馃敼 Revenue: $8.29B (Est. $8.33B) 馃敶; UP +2.5% YoY
馃敼 Organic Revenue Growth: 4.1% YoY
馃敼 Adj. Net Income: $1.79B (Est. $1.74B) 馃槓; UP +3% YoY
FY'25 Guidance
馃敼 Adj. EPS: $5.44-$5.50 (Est. $5.45) 馃煛
馃敼 Organic Revenue Growth: 4.75%-5%
Q3'25 Segments
馃敼 Cardiovascular Revenue: $3.04B (Est. $3.04B) 馃煛; UP +3.7% YoY
聽聽聽- Cardiac Rhythm & Heart Failure: $1.55B (Est. $1.53B) 馃煝; UP +5.1% YoY
聽聽聽- Structural Heart & Aortic: $874M (Est. $874.71M) 馃煛; UP +3.7% YoY
聽聽聽- Coronary & Peripheral Vascular: $618M (Est. $632.14M) 馃敶; UP +0.3% YoY
馃敼 Neuroscience Revenue: $2.46B (Est. $2.45B) 馃煝; UP +4.4% YoY
聽聽聽- Cranial & Spinal Technologies: $1.25B; UP +3.8% YoY
聽聽聽- Specialty Therapies: $732M; UP +0.8% YoY
聽聽聽- Neuromodulation: $476M; UP +12.0% YoY
馃敼 Medical Surgical Revenue: $2.07B (Est. $2.13B) 馃敶; DOWN -1.9% YoY
馃敼 Diabetes Revenue: $694M (Est. $681.77M) 馃煝; UP +8.4% YoY
Q3'25 Geographical Performance
馃敼 U.S. Revenue: $4.24B; UP +2.8% YoY
馃敼 International Revenue: $4.06B; UP +2.2% YoY
Announcements & Strategic Updates
馃敻 U.S. FDA approval for additional PFA manufacturing site in Galway
馃敻 CMS coverage for Renal Denervation expected by Oct 11, 2025
馃敻 Exclusive distribution agreement with Contego Medical for carotid stenting
Management Commentary
馃敻 CEO Geoff Martha: "We delivered strong earnings this quarter, with significant improvements in both our gross margin and operating margin on the back of our ninth quarter in a row of mid-single digit organic revenue growth."
馃敻 Interim CFO Gary Corona: "EPS came in above the high end of our guidance range. We were pleased with the operational performance of the business this quarter, turning mid-single digit organic growth into leveraged earnings."